Data review: More studies needed on water-based fibromyalgia therapies | NIH awards $11M for drug abuse studies involving social media | Study supports injections for treating chronic lower back pain
Web Version
 
October 22, 2014
News for the pain professional
SIGN UP|FORWARD|ARCHIVE|ADVERTISE

Pain Research News
Data review: More studies needed on water-based fibromyalgia therapies
Better-quality studies that include larger sample sizes and target long-term results are needed before determining the efficacy of using balneotherapy and hydrotherapy for fibromyalgia management, according to a study in Arthritis Research & Therapy. Researchers conducted a literature review of controlled trials for a range of balneotherapeutic and hydrotherapeutic treatments. Healio (free registration) (10/20)
Share: LinkedInTwitterFacebookGoogle+Email
NIH awards $11M for drug abuse studies involving social media
More than $11 million has been awarded by the NIH to researchers studying how social media can be used to improve the understanding, prevention and treatment of addiction and substance abuse. Studies include using social media to reduce prescription drug abuse among patients with chronic pain, developing techniques to mine social media for patterns of substance abuse, and determining whether social networks can support addiction recovery. MedicalDaily.com (10/17)
Share: LinkedInTwitterFacebookGoogle+Email
Treatment News
Study supports injections for treating chronic lower back pain
A study in the journal Pain Physician found transforaminal epidural injections may help treat chronic lower back pain in patients with diagnoses of disk herniation and radiculitis. The study compared lidocaine injections followed by either sodium chloride or betamethasone and tracked patients over two years as they continued to receive their usual pain management therapy. Pain Medicine News (10/2014)
Share: LinkedInTwitterFacebookGoogle+Email
FDA to give 3rd opioid drug its abuse-deterrent label
The FDA said Pfizer's pain medication Embeda, a combination of morphine and naltrexone, would be the third opioid drug to get an abuse-deterrent label. Study data showed that when the pill is crushed, eaten or snorted, naltrexone blocks the euphoric response. MedPage Today (free registration) (10/18)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
Policy & Trends
FDA issues draft guidance on development of migraine drugs
The FDA has released a draft of new recommendations for drugmakers developing migraine drugs. The proposed guidance covers statistical considerations, efficacy endpoints, dose selection, trial design and trial populations. "The purpose of this guidance is to assist sponsors in the clinical development of drugs for the acute treatment of migraines," the FDA wrote. The Hill (10/21)
Share: LinkedInTwitterFacebookGoogle+Email
Study evaluates medication errors among young children
An average of 63,358 medication errors occurred each year between 2002 and 2012 among children younger than age 6, according to a study in the journal Pediatrics. More than 25% of the errors involved children receiving the same medication twice, and the most common mistakes involved pain medications, followed by cough and cold medicines and allergy medicines. Reuters (10/20), DailyRx.com (10/19)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
SmartQuote
Minds are like parachutes; they work best when open."
-- Thomas Dewar,
Scottish businessman
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about APS ->About APS | Membership | Education | Resources | Journal of Pain
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Advertising:  Wynn Hansen
  P: 202.470.1149
 
 

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information